Saisei Ventures Invests in United Immunity, Co., Ltd., to Develop New Cancer Immune-Therapeutics Using Proprietary Immune Cell-Selective Delivery Technology
09/11/2023
Saisei News
New
Saisei Ventures is pleased to announce a new investment in United Immunity, a biotechnology company developing proprietary tumor-associated-macrophage-selective nanoparticles.
Saisei Ventures Enters into Letters of Intent with Healios and will Launch a Special Opportunities Co-Investment Fund
07/10/2023
Saisei News
Saisei Ventures is pleased to announce the signing of two letters of intent and will launch a new Special Opportunities co-investment fund.
Saisei Ventures is Selected as a Certified VC Fund by AMED to Catalyze the Japanese Drug Development Ecosystem
05/17/2023
Saisei News
Saisei Ventures is one of nine VC firms accredited by AMED for funding as part of its Drug Discovery Venture Ecosystem Enhancement Project.